Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective
Mark P. Jensen, Arnold R. Gammaitoni, Bradley S. Galer, et al.
Epilepsy Research (2022) Vol. 185, pp. 106976-106976
Closed Access | Times Cited: 16

Showing 16 citing articles:

Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
Adam Strzelczyk, Susanne Schubert‐Bast
CNS Drugs (2022) Vol. 36, Iss. 10, pp. 1079-1111
Open Access | Times Cited: 95
Dravet syndrome: A systematic literature review of the illness burden
Adam Strzelczyk, Lieven Lagae, Jo M. Wilmshurst, et al.
Epilepsia Open (2023) Vol. 8, Iss. 4, pp. 1256-1270
Open Access | Times Cited: 33
Fenfluramine: a plethora of mechanisms?
Jo Sourbron, Lieven Lagae
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 28
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
James E. Frampton
Drugs (2023) Vol. 83, Iss. 10, pp. 923-934
Open Access | Times Cited: 19
What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice
Adrián Valls Carbó, Álvaro Beltrán, I. Sánchez-Miranda Román, et al.
Epilepsy & Behavior (2024) Vol. 151, pp. 109620-109620
Closed Access | Times Cited: 8
Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment
Kim I. Bishop, Peter Κ. Isquith, Gérard A. Gioia, et al.
Epilepsy & Behavior (2022) Vol. 138, pp. 108994-108994
Closed Access | Times Cited: 25
Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice
Elaine Wirrell, Lieven Lagae, Ingrid E. Scheffer, et al.
Epilepsia Open (2024) Vol. 9, Iss. 5, pp. 1643-1657
Open Access | Times Cited: 6
Fenfluramine treatment for Dravet syndrome: Caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom
Mark P. Jensen, Arnold R. Gammaitoni, Rana Salem, et al.
Epilepsy Research (2023) Vol. 190, pp. 107091-107091
Open Access | Times Cited: 12
Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review
Vicente Villanueva, Víctor Soto Insuga, Patricia Smeyers, et al.
Neurology and Therapy (2025)
Open Access
Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study
Cathrine E. Gjerulfsen, Marina Nikanorova, Kern Olofsson, et al.
Epilepsia Open (2024) Vol. 9, Iss. 5, pp. 1891-1900
Open Access | Times Cited: 3
Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?
Nicola Pietrafusa, Marina Trivisano, Susanna Casellato, et al.
Epilepsia (2023) Vol. 65, Iss. 2
Open Access | Times Cited: 7
Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies
António Gil‐Nagel, J. Helen Cross, Orrin Devinsky, et al.
Epilepsia (2024) Vol. 65, Iss. 8, pp. 2186-2199
Open Access | Times Cited: 2
A comprehensive review of evolving treatment strategies for Dravet syndrome: Insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches
Debopam Samanta
Epilepsy & Behavior (2024) Vol. 162, pp. 110171-110171
Closed Access | Times Cited: 2
Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden
Chiara Malmberg, Magnus Värendh, Patric Berling, et al.
Applied Health Economics and Health Policy (2024) Vol. 22, Iss. 4, pp. 543-554
Closed Access | Times Cited: 1
Investigational new drugs for the treatment of Dravet syndrome: an update
Slobodan Јаnkovic, Snežana V. Janković, Radiša Vojinović, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 4, pp. 325-331
Closed Access | Times Cited: 2
Therapy outcomes associated with prescription cannabidiol use at 12 months post-initiation
Kayla Johnson, J. Barnes, Holly Dial, et al.
Epilepsy & Behavior (2023) Vol. 147, pp. 109412-109412
Closed Access | Times Cited: 1
Page 1

Scroll to top